AnaptysBio, Inc. (ANAB)
| Market Cap | 1.67B +167.8% |
| Revenue (ttm) | 232.39M +107.7% |
| Net Income | -26.79M |
| EPS | -0.95 |
| Shares Out | 29.10M |
| PE Ratio | n/a |
| Forward PE | 32.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 827,833 |
| Open | 58.37 |
| Previous Close | 56.77 |
| Day's Range | 55.16 - 58.44 |
| 52-Week Range | 17.11 - 73.30 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 87.09 (+51.44%) |
| Earnings Date | Aug 5, 2026 |
About ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ... [Read more]
Financial Performance
In 2025, AnaptysBio's revenue was $234.60 million, an increase of 157.01% compared to the previous year's $91.28 million. Losses were -$13.23 million, -90.89% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ANAB stock is "Strong Buy." The 12-month stock price target is $87.09, which is an increase of 51.44% from the latest price.
News
AnaptysBio assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of AnaptysBio (ANAB) with a Buy rating and $95 price target The company is now focused on its royalty-bearing assets, the analyst tells investors in a…
AnaptysBio price target raised to $90 from $85 at Leerink
Leerink raised the firm’s price target on AnaptysBio (ANAB) to $90 from $85 and keeps an Outperform rating on the shares. Although Q1 Jemperli collaboration revenue was below expectations, the…
AnaptysBio price target raised to $76 from $60 at UBS
UBS raised the firm’s price target on AnaptysBio (ANAB) to $76 from $60 and keeps a Buy rating on the shares.
AnaptysBio price target raised to $75 from $63 at Barclays
Barclays raised the firm’s price target on AnaptysBio (ANAB) to $75 from $63 and keeps an Overweight rating on the shares following the Q1 report. The company continues to execute…
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
Reports Q1 revenue $25.56M, consensus $18.87M. “Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli an...
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported...
AnaptysBio Earnings release: Q1 2026
AnaptysBio released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
AnaptysBio Quarterly report: Q1 2026
AnaptysBio has published its Q1 2026 quarterly earnings report on May 12, 2026.
AnaptysBio appoints Christopher Murphy as CFO
AnaptysBio (ANAB) announced the appointment of Christopher Murphy as CFO and Owen Hughes as a member of its board of directors. Murphy previously served as CFO and CBO of Third…
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce...
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announce...
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
Piper Sandler lowered the firm’s price target on AnaptysBio (ANAB) to $93 from $95 and keeps an Overweight rating on the shares. The firm notes that on April 2026, AnaptysBio…
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...
AnaptysBio price target raised to $85 from $66 at Leerink
Leerink raised the firm’s price target on AnaptysBio (ANAB) to $85 from $66 and keeps an Outperform rating on the shares.
GSK’s TESARO provides update on AnaptysBio litigation
GSK (GSK) subsidiary, TESARO, confirms that the Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio (ANAB) against TESARO’s claim for anticipatory breach. The court’s ruling ...
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
AnaptysBio (ANAB) announced that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys’ position that it has never re...
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announ...
AnaptysBio price target lowered to $60 from $90 at UBS
UBS lowered the firm’s price target on AnaptysBio (ANAB) to $60 from $90 and keeps a Buy rating on the shares.
AnaptysBio price target lowered to $63 from $79 at Barclays
Barclays lowered the firm’s price target on AnaptysBio (ANAB) to $63 from $79 and keeps an Overweight rating on the shares. Following the spinoff, AnaptysBio is a pureplay royalty company…
AnaptysBio price target lowered to $60 from $90 at UBS
UBS lowered the firm’s price target on AnaptysBio (ANAB) to $60 from $90 and keeps a Buy rating on the shares. Following the spin-off of its biopharma business into First…
AnaptysBio completes separation of First Tracks Biotherapeutics
AnaptysBio (ANAB), announced the completion of its spin-off of First Tracks Biotherapeutics, its former biopharma operations business. “Anaptys begins this next chapter in a virtual business model. We...
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its f...
AnaptysBio price target raised to $95 from $67 at Piper Sandler
Piper Sandler raised the firm’s price target on AnaptysBio (ANAB) to $95 from $67 and keeps an Overweight rating on the shares. The firm notes AnaptysBio has traded up about…
AnaptysBio announces $100M share repurchase program
AnaptysBio (ANAB) announced that its board of directors has authorized a stock repurchase plan under which the company may repurchase up to $100M of the company’s outstanding common stock, par…
AnaptysBio board approves spin-off of First Tracks Biotherapeutics
AnaptysBio (ANAB) announced that its board of directors has approved the previously announced spin-off of First Tracks Biotherapeutics. The new company is expected to begin “regular-way” trading on Na...